VivoSeq
Other

Intraperitoneal Chemotherapy

0

Pipeline Programs↗

7

Active Trials↗

0

Companies Involved↗

Intraperitoneal Chemotherapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

62/100

Attrition Rate

22/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed8 · 35%
Recruiting6 · 26%
Unknown status3 · 13%
Terminated3 · 13%
Withdrawn2 · 9%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

23 trials

Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Recruiting·—·Phase 2·NCT03127774·30 enrolled
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Recruiting·TThe Netherlands Cancer Institute·Phase 3·NCT03772028·538 enrolled
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
Recruiting·CCiusss de L'Est de l'Île de Montréal·Phase 2·NCT05913674·25 enrolled
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
Recruiting·UUppsala University·Phase 3·NCT04861558·213 enrolled
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05415709·45 enrolled
A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.
Recruiting·HHospital General Universitario Gregorio Marañon·Phase 2·NCT07229040·90 enrolled
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
Not yet recruiting·FFudan University·Phase 2·NCT06544460·94 enrolled
Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00006038
The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial
Completed·YYonsei University·N/A·NCT03370588·56 enrolled
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Completed·WWake Forest University Health Sciences·Phase 2·NCT03188432·50 enrolled
Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway
Completed·MM.D. Anderson Cancer Center·Phase 3·NCT03359811·75 enrolled
The Intraoperative Physiologic Changes of Patients Under Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Prospective Observational Study
Completed·YYonsei University·N/A·NCT02325648·22 enrolled
Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy
Completed·FFar Eastern Memorial Hospital·N/A·NCT05410938·59 enrolled
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01767675·99 enrolled
Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
Completed·UUppsala University·Phase 3·NCT01524094·49 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)